Your PSA of 0.26 ng/mL is excellent news and indicates continued biochemical control after radical prostatectomy
Your current PSA of 0.26 ng/mL, while technically detectable, remains well below the AUA threshold for biochemical recurrence (0.2 ng/mL confirmed by a second value ≥0.2 ng/mL), and the downward trend your provider noted is the most important favorable prognostic sign. 1
Understanding Your Result in Context
Why This PSA Level Is Reassuring
The AUA definition of biochemical recurrence requires an initial PSA ≥0.2 ng/mL followed by a subsequent confirmatory PSA ≥0.2 ng/mL. A single value at 0.26 ng/mL does not meet this definition—you need two consecutive values at or above 0.2 ng/mL. 1
Your provider specifically noted the PSA is "trending down," which is the critical favorable feature. A rising trend (not a single value) defines recurrence. 2
PSA should become undetectable (typically <0.1 ng/mL) within 6–8 weeks after radical prostatectomy due to its biological half-life of 2–3 days. However, ultrasensitive assays can detect very low levels that may fluctuate without clinical significance. 3, 4
The Importance of PSA Kinetics Over Absolute Values
A downward PSA trend, even when detectable, indicates ongoing clearance of residual PSA from surgical manipulation or benign prostatic tissue remnants, not cancer recurrence. 5, 3
Recent 2025 data from 30,000+ patients showed that some men with initially detectable PSA after prostatectomy eventually reach undetectable levels when given adequate time (median 3–4 months), particularly when post-operative therapy is not rushed. 5
PSA doubling time <6 months is the high-risk feature that triggers early salvage therapy; a falling PSA has the opposite implication. 2
What You Should Do Next
Immediate Monitoring Plan
Repeat PSA in 4–6 weeks on the same Roche ECLIA platform your lab uses. Switching assay methods introduces ±25% variability and makes trend interpretation impossible. 6
If the next PSA is lower or stable below 0.2 ng/mL, continue quarterly monitoring for the first year, then every 6 months. 2, 6
If the next PSA rises above 0.2 ng/mL, obtain a third confirmatory value before concluding biochemical recurrence has occurred. 1, 2
When to Escalate Evaluation
Do not pursue imaging (PSMA-PET or conventional) at this PSA level with a downward trend. Imaging is reserved for confirmed biochemical recurrence with rising kinetics. 2, 6
If two consecutive PSA values ≥0.2 ng/mL are documented and rising, then PSMA-PET/CT becomes the preferred staging modality to guide salvage radiotherapy planning. 2, 6
Early salvage radiotherapy is most effective when PSA is <0.5 ng/mL and preferably <0.2 ng/mL, but only after confirming a rising trend—not based on a single detectable value. 2
Critical Pitfalls to Avoid
Do not interpret a single PSA of 0.26 ng/mL as biochemical recurrence. The AUA definition requires confirmation with a second value ≥0.2 ng/mL, and your provider has already noted a downward trend. 1
Do not switch PSA assay platforms during follow-up. Your lab uses Roche ECLIA methodology; all future tests must use the same method to avoid spurious changes. 6
Do not pursue salvage therapy based on a single detectable PSA when the trend is favorable. Overtreatment based on isolated values leads to unnecessary morbidity (incontinence, erectile dysfunction). 2, 5
Do not delay repeat PSA testing beyond 6–8 weeks. Establishing kinetics early allows timely intervention if recurrence is confirmed, while avoiding premature treatment if PSA continues to fall. 2, 5
Your Free PSA and Percent Free PSA
The free PSA of 0.26 ng/mL and percent free of 6.2% are not interpretable in the post-prostatectomy setting. These metrics are used for prostate cancer screening in men with intact prostates and total PSA 4–10 ng/mL. 7, 8
After radical prostatectomy, only total PSA kinetics matter for detecting recurrence. The lab report's reference to Catalona's percent free PSA table applies to screening, not post-surgical surveillance. 7
Bottom Line
Your PSA of 0.26 ng/mL with a downward trend does not meet criteria for biochemical recurrence and is consistent with ongoing PSA clearance after surgery. Repeat testing in 4–6 weeks will clarify whether this represents benign fluctuation or the beginning of a concerning rise. Your provider's assessment that this is a "good sign" is accurate. 1, 2, 5